Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899457 · ClinicalTrials.gov registry record
Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants
A clinical trial of Lung Cancer and Healthy, no Evidence of Disease, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 37
- Enrollment target
- 3
- Study locations
NCT00899457: Completed study of Lung Cancer and Healthy, no Evidence of Disease, sponsored by Vanderbilt-Ingram Cancer Center.
NCT00899457 is a study of Lung Cancer and Healthy, no Evidence of Disease that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 37 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00899457, a study of Lung Cancer and Healthy, no Evidence of Disease, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Studying samples of blood, urine, sputum, mouth cells, and bronchial tissue from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about the development of cancer. PURPOSE: This laboratory study is looking for molecular markers in predicting lung cancer development using tissue samples from healthy participants.
Primary Outcome
Specimens are collected from healthy participants with no known risk of lung cancer
Conditions Studied
Interventions
- OTHER biologic sample preservation procedure
- OTHER laboratory biomarker analysis
- PROCEDURE bronchoscopy
- GENETIC proteomic profiling
Study Locations (3)
Tennessee
- Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
- Vanderbilt-Ingram Cancer Center at Franklin - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-08 |
What the finished NCT00899457 record still lists
NCT00899457 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which biologic sample preservation procedure is the first listed.
NCT00899457 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00899457 about?
NCT00899457 is a clinical study titled "Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants". RATIONALE: Studying samples of blood, urine, sputum, mouth cells, and bronchial tissue from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about the development of cance...
What is the current status of trial NCT00899457?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2008-04. Estimated completion is 2010-08.
What conditions does trial NCT00899457 study?
This clinical trial studies the following conditions: Lung Cancer, Healthy, no Evidence of Disease.
What interventions are being tested in trial NCT00899457?
The interventions under investigation include: biologic sample preservation procedure (OTHER), laboratory biomarker analysis (OTHER), bronchoscopy (PROCEDURE), proteomic profiling (GENETIC).
Who is sponsoring clinical trial NCT00899457?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00899457 being conducted?
This trial has 3 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00899457's enrollment target sits among peer trials
37 307th of 409 higher than 100 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia